These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33278499)

  • 1. Hypoxia-mediated drug resistance in breast cancers.
    McAleese CE; Choudhury C; Butcher NJ; Minchin RF
    Cancer Lett; 2021 Apr; 502():189-199. PubMed ID: 33278499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment.
    Zhi S; Chen C; Huang H; Zhang Z; Zeng F; Zhang S
    Front Immunol; 2024; 15():1370800. PubMed ID: 38799423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2 -induced doxorubicin resistance in breast cancer cells.
    Li Z; Zhu Q; Hu L; Chen H; Wu Z; Li D
    Cancer Sci; 2015 Aug; 106(8):1041-9. PubMed ID: 26079208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer.
    Jögi A; Ehinger A; Hartman L; Alkner S
    PLoS One; 2019; 14(12):e0226150. PubMed ID: 31821370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome.
    Kim JY; Lee JY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-glucan from Lentinus edodes inhibits breast cancer progression via the Nur77/HIF-1α axis.
    Zhang X; Li T; Liu S; Xu Y; Meng M; Li X; Lin Z; Wu Q; Xue Y; Pan Y; Alitongbieke G
    Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33245358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
    Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M
    J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.
    Smollich M; Götte M; Kersting C; Fischgräbe J; Kiesel L; Wülfing P
    Breast Cancer Res Treat; 2008 Mar; 108(2):175-82. PubMed ID: 17468950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-inducible factor-1 in human breast and prostate cancer.
    Kimbro KS; Simons JW
    Endocr Relat Cancer; 2006 Sep; 13(3):739-49. PubMed ID: 16954428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.
    Maroufi NF; Amiri M; Dizaji BF; Vahedian V; Akbarzadeh M; Roshanravan N; Haiaty S; Nouri M; Rashidi MR
    Eur J Pharmacol; 2020 Aug; 881():173282. PubMed ID: 32580038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecules targeting HIF-1α pathway for cancer therapy in recent years.
    Tang W; Zhao G
    Bioorg Med Chem; 2020 Jan; 28(2):115235. PubMed ID: 31843464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.
    Brooks DL; Schwab LP; Krutilina R; Parke DN; Sethuraman A; Hoogewijs D; Schörg A; Gotwald L; Fan M; Wenger RH; Seagroves TN
    Mol Cancer; 2016 Mar; 15():26. PubMed ID: 27001172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1α synthesis, and decreases breast cancer metastasis.
    Wei Z; Shan Y; Tao L; Liu Y; Zhu Z; Liu Z; Wu Y; Chen W; Wang A; Lu Y
    Mol Carcinog; 2017 Oct; 56(10):2317-2331. PubMed ID: 28574600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
    Méndez-Blanco C; Fondevila F; García-Palomo A; González-Gallego J; Mauriz JL
    Exp Mol Med; 2018 Oct; 50(10):1-9. PubMed ID: 30315182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.
    Yehia L; Boulos F; Jabbour M; Mahfoud Z; Fakhruddin N; El-Sabban M
    PLoS One; 2015; 10(6):e0129356. PubMed ID: 26046764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy.
    Ma Z; Wang LZ; Cheng JT; Lam WST; Ma X; Xiang X; Wong AL; Goh BC; Gong Q; Sethi G; Wang L
    Antioxid Redox Signal; 2021 Jun; 34(18):1484-1497. PubMed ID: 33198508
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors.
    Semenza GL
    Clin Sci (Lond); 2015 Dec; 129(12):1037-45. PubMed ID: 26405042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of HIF-1α-mediated metabolic adaption by NRF2-silencing in breast cancer cells.
    Lee S; Hallis SP; Jung KA; Ryu D; Kwak MK
    Redox Biol; 2019 Jun; 24():101210. PubMed ID: 31078780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
    Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
    Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.